内容来源：https://www.technologyreview.com/2026/06/30/1139987/claude-science-is-anthropics-newest-flagship-product/

内容总结：

Anthropic发布旗舰产品Claude Science，剑指AI+科学领域

Anthropic于周二正式推出其最新旗舰产品——Claude Science，旨在为科学研究提供与Claude Code在软件工程领域同等水平的自动化支持。在面向制药企业高管、生物技术创始人及研究人员的发布会上，该公司展示了这一具备自主执行能力的新产品，其特色在于能够基于简洁的高层级指令完成复杂科研任务，并可调用计算生物学与药物研发领域的专用工具。

作为继Claude Code、Claude Cowork后的第三大核心产品，Claude Science现已向所有付费用户开放。与去年10月推出的"Claude for Life Sciences"插件不同，本次发布的是功能完整的独立产品。Anthropic生命科学负责人Eric Kauderer-Abrams强调："这一产品序列安排彰显了科学应用对我们使命的重要性——开发服务于人类长期福祉的AI，而生命科学正是实现这一目标的最大机遇。"

在竞争格局方面，曾引领AI科学革命的DeepMind正面临挑战。尽管其AlphaFold模型及CEO Demis Hassabis、研究员John Jumper曾获诺贝尔化学奖，但在大语言模型最赚钱的编程应用场景中，DeepMind已显落后。Anthropic则具备独特优势：CEO Dario Amodei拥有科学博士学位，且本月早些时候，DeepMind核心科学家Jumper已宣布加盟Anthropic。

据哈佛物理学家Matthew Schwartz基于实测评估，Anthropic的Opus 4.5模型在科研项目执行能力上已相当于二年级研究生水平。Claude Science在继承Code与Cowork功能基础上，新增了集群计算管理、可追溯结果复现等关键能力。虽然理论支持所有科学领域，但产品明显聚焦于分子与细胞生物学，特别是药物开发——在发布会上，其开发负责人Alexander Tarashansky演示了系统如何自主识别苯丙酮尿症的新药候选分子。

值得注意的是，Anthropic不仅为药企和高校提供工具，还将亲自动手。这家公司宣布将利用Claude Science自主开展针对被忽视疾病的药物研发，既为推进科学，也为在真实场景中检验产品效能。分析认为，此举兼顾人道主义价值与商业考量——在IPO临近的当下，制药巨头丰厚的合同将有助于公司持续盈利。

中文翻译：

克劳德科学是Anthropic最新推出的旗舰产品。该公司正加倍押注人工智能在科学领域的应用。在周二面向制药公司高管、生物技术创始人及研究人员的发布会上，Anthropic发布了重大新产品Claude Science，旨在以克劳德代码（Claude Code）支持软件工程的方式支持科学研究。与Claude Code类似，Claude Science在收到简洁的高层次指令后能够自主执行有意义的工作，并且它配备的工具使其在计算生物学和药物研发领域尤为实用。除了发布和预览现已对所有付费Claude用户开放的Claude Science外，Anthropic还宣布将利用该产品开展自身针对罕见、被忽视疾病药物的研究。

这并非Anthropic首次涉足科学领域的AI应用。去年10月，该公司发布了插件，帮助Claude在“克劳德生命科学”框架下利用科学软件和数据库。但与早期版本不同，Claude Science是一款功能完备的独立产品。Anthropic决定将Claude Science提升至与Claude Code和Claude Cowork同等的地位，表明该公司正非常严肃地对待人工智能的科学应用——或者至少希望给人留下这样的印象。

Anthropic生命科学负责人埃里克·考德雷尔-艾布拉姆斯表示：“这体现了这项工作对我们的使命有多重要，它能与Claude Code和Claude Cowork并列，成为我们接下来发布的重要产品。我们的使命是开发服务于人类长期福祉的人工智能，我们相信实现这一目标的最大机会存在于生命科学领域。”

过去十年，一家公司——谷歌DeepMind——一直处于科学AI领域的前沿。首席执行官德米斯·哈萨比斯和研究员约翰·江珀因在AlphaFold模型上的工作获得了诺贝尔化学奖，DeepMind还在气象学、材料科学等多个学科做出了重大贡献。但在过去几个月中，AI快速发展的前沿似乎已将DeepMind远远甩在身后。在编码这一大语言模型最赚钱的应用领域，DeepMind仍在努力追赶。

Anthropic具备接替DeepMind科学领头羊地位的有利条件。与哈萨比斯一样，Anthropic首席执行官达里奥·阿莫代也是一位拥有博士学位的科学家——这与彻头彻尾商人的OpenAI首席执行官萨姆·奥尔特曼不同。许多科学家已经是Claude Code等工具的热心用户。如今，大量科学研究都涉及一定量的编码工作，但并非所有科学家都是专业的软件工程师，因此像Claude Code这样的工具能极大提升他们的生产力。而该公司最近也获得了科学界的一项重要信任票：本月初，江珀宣布离开DeepMind加入Anthropic。

自2025年底，由大语言模型（包括Anthropic的Opus系列模型）驱动的智能体能够执行有用的独立工作以来，科学家们一直在见证它们的能力上限。在Anthropic官网发布的一篇博文中，哈佛大学物理学家马修·施瓦茨根据自己使用Claude Code和其他Anthropic工具的经验估算，该公司的Opus 4.5模型在执行科学项目方面的能力约相当于二年级研究生水平。

据考德雷尔-艾布拉姆斯透露，Claude Science并非旨在取代科学家工作流程中的Claude Code和Claude Cowork。相反，它旨在科学家已发现的Anthropic产品有用之处上加以拓展。例如，它不仅能编写代码，还能帮助科学家在强大的计算机集群上运行代码——这是许多科学家工作所需但难以管理的事情。同时，它优先考虑可重复性，使科学家能够追溯任何图表或结果的来源，并检查其准确性和有效性。

尽管Claude Science原则上可以协助任何科学领域的研究，但它似乎被设计并定位为分子与细胞生物学，特别是药物研发的工具。它能与遗传学、化学和蛋白质生物学领域使用的多种工具交互，这些工具对寻找新药的研究者都可能派上用场。在周二的发布会上，主导Claude Science开发的亚历山大·塔拉尚斯基演示了该系统如何自主识别治疗苯丙酮尿症（一种罕见遗传病）的新候选药物。

而且，Anthropic并未将所有工作留给出席活动的制药公司和大学实验室。借助Claude Science，该公司将自行开展针对被忽视疾病候选药物的研究——既是为了推动科学进步，也是为了更清晰地了解Claude Science在现实世界中的运作方式。

在创建通用科学研究工具时优先考虑药物研发有着显而易见的人道主义原因，AI行业领袖也常将治愈疾病列为该技术的重大潜在优势。但同样值得注意的是，制药公司的财力远比学术研究机构雄厚。Anthropic表示即将迎来首个盈利季度，如果与制药公司的大型新合同陆续落地，随着“刷Token热潮”逐渐冷却，这些合同将有助于确保公司保持盈利——这对于计划今年晚些时候进行的IPO而言愈发重要。

深度探索
人工智能
美国面向基督徒的新手机网络旨在屏蔽色情及性别相关内容
该手机套餐将于下周在T-Mobile网络上推出，采取核武器式方法保障网络安全。
一家初创公司声称突破了制约大语言模型的瓶颈
Subquadratic现已分享其新模型的更多细节，但部分人士仍持怀疑态度。
马斯克诉奥尔特曼第一周：埃隆·马斯克称自己受骗，警告AI可能毁灭全人类，并承认xAI蒸馏了OpenAI的模型
马斯克保持冷静，而OpenAI的律师则用尖锐问题就他起诉动机对其进行猛烈抨击。
对AI就业恐慌的现实检验
数据究竟如何揭示人工智能对劳动力市场的影响？答案可能让你惊讶。
保持联系
获取麻省理工科技评论的最新资讯
发现特别优惠、热门故事、即将到来的活动等更多内容。

英文来源：

Claude Science is Anthropic’s newest flagship product
The company is doubling down on AI for science.
At an event for pharmaceutical executives, biotech founders, and researchers on Tuesday, Anthropic announced Claude Science, a major new product intended to support scientific research in the same way that Claude Code supports software engineering. Like Claude Code, Claude Science can autonomously carry out meaningful work when given concise, high-level instructions, and it has access to tools that make it particularly useful for research in computational biology and drug development. Along with launching and previewing Claude Science, which is now available to all paid Claude subscribers, Anthropic also announced that it will be using the product to pursue some of its own research into drugs for rare, neglected diseases.
This is not Anthropic’s first foray into AI for science. In October, the company released plug-ins that help Claude make use of scientific software and databases under the heading “Claude for Life Sciences.” But unlike this earlier release, Claude Science is a full-featured, standalone product. Anthropic’s decision to elevate Claude Science to the same rank as Claude Code and Claude Cowork indicates that the company is taking AI’s scientific applications very seriously—or at least wants to give the impression that it is.
“It represents how important this is to our mission that this is right up there with Claude Code and Claude Cowork as the next really significant product that we’re releasing,” says Eric Kauderer-Abrams, Anthropic’s head of life sciences. “Our mission is to develop AI that serves humanity’s long-term well-being, and we believe that by far the greatest opportunity to do that is in the life sciences.”
For the past decade, one company—Google DeepMind—has been at the vanguard of AI for science. CEO Demis Hassabis and researcher John Jumper won the Nobel Prize in chemistry for their work on the company’s AlphaFold model, and DeepMind has also made major contributions to meteorology, materials science, and a variety of other disciplines. But in the past several months, the fast-advancing frontier of AI progress seems to have left DeepMind in the dust. When it comes to coding, which has become the most lucrative use case for LLMs, DeepMind is stuck playing catch-up.
Anthropic is well positioned to take up DeepMind’s scientific mantle. Like Hassabis, Anthropic CEO Dario Amodei is a PhD scientist—unlike OpenAI CEO Sam Altman, who’s a businessman through and through. Many scientists are already avid users of tools such as Claude Code. These days, a lot of scientific research involves some amount of coding, but not all scientists are expert software engineers, and so tools like Claude Code can make a huge difference for their productivity. And the company has recently earned a major scientific vote of confidence: Earlier this month, Jumper announced that he is leaving DeepMind for Anthropic.
Since agents powered by LLMs, including Anthropic’s Opus model series, became capable of useful, independent work in late 2025, scientists have been seeing just how much they can do. In a blog post published on Anthropic’s website, the Harvard physicist Matthew Schwartz estimated, on the basis of his work with Claude Code and other Anthropic tools, that the company’s Opus 4.5 model is about as capable of executing scientific projects as a second-year graduate student.
According to Kauderer-Abrams, Claude Science isn’t intended to displace Claude Code and Claude Cowork in scientists’ workflows. Instead, it’s designed to build on what scientists already find useful about Anthropic’s products. For instance, it not only writes code but also helps scientists run their code on powerful computer clusters, which many many scientists need for their work but can be difficult to manage. And it prioritizes reproducibility, so that scientists can trace back the source of any figure or result and check it for accuracy and validity.
Though Claude Science could in principle assist with any area of scientific research, it seems designed and marketed as a tool for molecular and cellular biology, and for drug development in particular. It can interface with various tools used in genetics, chemistry, and protein biology, all of which could come in handy for researchers on the hunt for new drugs. During the Tuesday event, Alexander Tarashansky, who led the development of Claude Science, demonstrated how the system could autonomously identify new drug candidates for phenylketonuria, a rare genetic disease.
And Anthropic isn’t leaving all that work to the pharma companies and university labs that were represented at the event. Armed with Claude Science, it will be pursuing its own research into drug candidates for neglected diseases—both to help move science forward and to gain a clearer sense of how Claude Science works in the real world.
There are obvious humanitarian reasons to prioritize drug development when creating a general-purpose scientific research tool, and AI industry leaders often cite curing disease as a major potential upside of the technology. But it’s also notable that pharmaceutical companies have far deeper pockets than academic researchers. Anthropic says it’s set to see its first profitable quarter, and if major new contracts with pharmaceutical companies are forthcoming, they could help ensure it stays profitable as the tokenmaxxing craze dies down—something that’s ever more important as an IPO approaches later this year.
Deep Dive
Artificial intelligence
A new US phone network for Christians aims to block porn and gender-related content
Launching next week on T-Mobile's network, the cell plan takes a nuclear approach to online safety.
A startup claims it broke through a bottleneck that’s holding back LLMs
Subquadratic has now shared more details about its new model. But some are still skeptical.
Musk v. Altman week 1: Elon Musk says he was duped, warns AI could kill us all, and admits that xAI distills OpenAI’s models
Musk kept his cool, and OpenAI’s lawyer bulldozed him with piercing questions about his motivations for suing the company.
A reality check on the AI jobs hysteria
What do the numbers really say about the impact of artificial intelligence on the labor market? The answer might surprise you.
Stay connected
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.